

Category	Title	Description	Lead	Due Date	Current update (DATE)	RAG
Advisory Board	eMDT Digital System	Review the haemato-oncology specific data sets and definitions to ensure they remain fit for purpose and supplement the agreed 'core' data set for the application.	MCN Clinical Lead MCN&I Manager MCN Members	Mar-27		
Advisory Board	Complete analysis of audit of SMC approved medicines to assess service impact	Complete analysis of audit and report findings. Revisit to assess if MCN is in agreement that this is a useful exercise to help plan service provision and development.	MCN Clinical Lead MCN&I Manager WoS Pharmacy Team MCN Members Advisory Board	May-26		
Advisory Board	Rationalisation and coordination of testing for haematological malignancies in the WoS	Identify other areas where regional diagnostic testing pathways would be appropriate and produce a phased plan for development. Conclude the development of a CMG for Germline Predisposition. Submit SG-TAG to expand Myeloid NGS panel scope.	MCN Clinical Lead Molecular Diagnostics Subgroup	Mar-27 June-26 Mar-27		
Advisory Board	Assess the regional expansion of an improvement project identifying early integration of palliative care needs assessment within haematology	Complete analysis and report findings Assess appropriate expansion regionally Assess appropriate expansion to wider patient group	WOSCAN clinicians Dr P Glancey Dr G Home MCN Clinical Lead MCN&I Manager	Mar-27		
Advisory Board	Undertake an improvement project on the management of menstrual bleeding in patients receiving SACT treatment	Identify and approach appropriate clinical, managerial and service leads withing NHSGGC to gain commitment to and sign off for project. Produce regional guideline	WOSCAN clinicians Dr L Knox Dr A Laing Dr J Burgess Gynaecology clinician MCN Clinical Lead MCN&I Manager	Mar-27		
Advisory Board	Regional/National Clinical Management Guidelines (CMGs) and Clinical Guidance Documents (CGDs)	CMGs <ul style="list-style-type: none"> • Management of newly presenting patients with a mediastinal mass causing airway compromise • Scottish CMG for Classical Hodgkin Lymphoma • Primary Cutaneous Lymphoma • Myeloma • Polycythaemia Vera PRV • Primary CNS Lymphoma • Hairy Cell Leukemia • Scottish Consensus CMG CLL • Scottish Consensus CMG for Follicular NHL • Acute Lymphoblastic Leukaemia CGDs <ul style="list-style-type: none"> • Recommended Screening and Preventative Practices for Adult Long-Term Survivors after Allogeneic Haemopoietic Stem Cell Transplant and TBI Autografts • Good practice framework to support the development of nurse led clinics in haemato-oncology • Acute Leukaemia Regional Follow-up Guideline 	MCN Clinical Lead MCN&I Manager MCN Members	May-26 May-26 May-26 May-26 Sep-26 Nov-26 Dec-26 Dec-26 Mar-27 Mar-27 Aug-26 May-26 Aug-26		
Advisory Board	Clinical Audit Data	Review QPI audit findings to identify variation in practice, identify requirements for further data analysis to aid understanding of variance and develop action/ improvement plan. Monitor and ensure progress with regional and local board action/improvement plans.	MCN Clinical Lead MCN&I Manager Information Team Clinical Effectiveness Leads	Apr-26 July-26 Mar-27		
Advisory Board	MCN Education Event	Develop a focused programme and establish data requirements. Develop action plans arising from the event and monitor progress of agreed actions.	MCN Clinical Lead MCN&I Manager	Oct-26 Mar-27		
Advisory Board	Service Configuration Maps	Update activity following publication of audit report.	MCN&I Manager	Sep-26		